BiotechTube
Aerska

Aerska

Dublin, Ireland· Est.
aerska.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Aerska is a private, pre-clinical biotech founded in 2011, aiming to unlock RNAi therapeutics for central nervous system (CNS) disorders by overcoming the blood-brain barrier delivery challenge. The company recently raised a $39M Series A round led by EQT Dementia Fund and age1 to advance its platform. It is led by a team with deep expertise in RNAi, CNS drug development, and biotech entrepreneurship, building on recent advances in brain shuttle technologies to systemically deliver its medicines.

NeurologyNeurodegenerative Diseases

Technology Platform

Platform combining next-generation RNA interference (RNAi) therapeutics with systemic brain shuttle technologies designed to cross the blood-brain barrier (BBB).

Opportunities

The massive, unmet need in neurodegenerative diseases like Alzheimer's creates a multi-billion dollar market for disease-modifying therapies.
Successfully validating a systemic RNAi delivery platform for the brain would also create significant platform value, enabling partnerships and application across numerous CNS disorders.

Risk Factors

The core technology risk is the unproven ability to reliably and safely deliver RNAi therapeutics across the human blood-brain barrier at therapeutic doses.
The company also faces the long, costly, and high-failure-rate pathway inherent in CNS drug development and significant competition in the emerging field of CNS genetic medicines.

Competitive Landscape

Aerska competes in the emerging field of CNS-targeted genetic medicines, facing competition from other biotechs developing various modalities (ASOs, gene therapy, RNAi) and delivery methods (intrathecal injection, novel BBB shuttles). Its key differentiator is the focus on systemic delivery of RNAi, competing directly with companies like Alnylam (which has CNS programs) and newer entrants, requiring rapid execution to establish a leading position.

More companies in RNA Therapeutics (non-mRNA) →More companies in Ireland →